CTP-543

An investigational JAK 1/2 inhibitor for alopecia areata

Concert Pharmaceuticals is developing CTP-543, an oral selective inhibitor of Janus kinases JAK1 and JAK2, as a potential treatment for alopecia areata.

Janus kinases (JAKs) are a group of enzymes that play an important role in the immune system. Research has shown that inhibiting JAKs can be beneficial in treating certain immune-mediated diseases. Concert was one of the first drug developers to leverage recent research about JAK inhibitors to develop CTP 543 as a potential new treatment to address the dysregulated autoimmune function in alopecia areata. CTP-543 is a deuterium-modified form of the JAK 1/2 inhibitor ruxolitinib.

Alopecia areata is a serious autoimmune disease with no approved treatment

Alopecia areata is an autoimmune disease in which the body’s immune system mistakenly attacks a person’s hair follicles, causing patchy or complete loss of hair on the scalp and body as well as other significant physical and psychological symptoms. Alopecia areata affects up to 650,000 Americans at any given time and can be debilitating to their physical and psychological health.

The FDA selected alopecia areata as a disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017, with the goal to bring patient perspectives into early-stage drug development. Currently, no drugs are approved by the FDA for the treatment of alopecia areata.

CTP-543 Clinical Program and Progress

Concert has an ongoing robust clinical program evaluating CTP-543 as an oral medicine for the treatment of alopecia areata. The FDA has granted Fast Track designation for CTP-543. The core clinical program includes a Phase 2 study evaluating a range of doses in different cohorts of patients with alopecia areata, designed to identify the optimal dose for efficacy and safety for future pivotal testing. Additionally, Concert is conducting several open label studies comparing once-daily (QD) and twice-daily (BID) oral dosing to inform the optimal dosing regimen.

CTP-543 in the Clinic

PHASE 2 STUDY
OPEN LABEL TRIALS
Open Label Dosing Regimen Trials
OPEN LABEL 1
8 mg BID or 16 mg QD

OPEN LABEL 2
12 mg BID or 24 mg QD
Continued enrollment of patients from CTP-543 trials

To learn more about Concert’s sponsored clinical trials, please visit clinicaltrials.gov:

Back to Top